AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7953209 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental units (E) received feedback on the first measurement and one unit received special intervention concerning documentation.
Number of subjects: 120
Study 7953209 — intervention group
Group type: COMPARATOR
Intervention: Control units (C) did not receive feedback or special intervention.
Number of subjects: 120
Study 3314798 — intervention group
Group type: EXPERIMENTAL
Intervention: Acifran 100 mg t.i.d.
Number of subjects: 14
Study 3314798 — intervention group
Group type: EXPERIMENTAL
Intervention: Acifran 300 mg t.i.d.
Number of subjects: 14
Study 3314798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30476108 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (200 mg) administered three times daily for 2 days, then once daily.
Number of subjects: 160
Study 27312961 — intervention group
Group type: EXPERIMENTAL
Intervention: Home modifications (e.g., handrails, grab rails, outside lighting, edging for outside steps, slip-resistant surfacing)
Number of subjects: 0
Study 27312961 — intervention group
Group type: EXPERIMENTAL
Intervention: Home modifications
Number of subjects: 0
Study 27097430 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine hemorrhoids lotion for fumigation
Number of subjects: 348
Study 27097430 — intervention group
Group type: COMPARATOR
Intervention: 1 000 mL 1: 5 000 potassium permanganate solution for sitz bath
Number of subjects: 348
Study 23380913 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg folic acid
Number of subjects: 2508
Study 23380913 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg folic acid
Number of subjects: 2508
Study 23380913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined folic acid groups (0.4 mg and 4 mg)
Number of subjects: 2508
Study 21153694 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (3-sessions)
Number of subjects: 6987
Study 21153694 — intervention group
Group type: COMPARATOR
Intervention: Group B (1-session)
Number of subjects: 6987
Study 21153694 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (3-sessions) completers
Number of subjects: 6987
Study 18030540 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coach support (N = 70)
Number of subjects: 275
Study 18030540 — intervention group
Group type: COMPARATOR
Intervention: Brochure support (N = 66)
Number of subjects: 275
Study 18030540 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coach support for patients needing no support (N = 49)
Number of subjects: 275
Study 18030540 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who declined support (N = 41)
Number of subjects: 275
Study 18030540 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who could not be contacted (N = 49)
Number of subjects: 275
Study 16534471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus (CMV) immune globulin
Number of subjects: 146
Study 16534471 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 146
Study 14652439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg Q6H
Number of subjects: 97
Study 14652439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 10224639 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management therapy with choice of target (behavioral or cognitive)
Number of subjects: 40
Study 10224639 — intervention group
Group type: COMPARATOR
Intervention: Self-management therapy without choice of target
Number of subjects: 40
Study 10224639 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management therapy with choice of target
Number of subjects: 40
Study 9085491 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg dose of ritanserin
Number of subjects: 8
Study 9085491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1813200 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (0.3% Triclosan and 2.0% copolymer)
Number of subjects: 121
Study 1813200 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 121
Study 6401550 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 40 mg/kg
Number of subjects: 0
Study 6401550 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with niridazole 25 mg/kg and metrifonate 10 mg/kg
Number of subjects: 0
Study 6401550 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate 10 mg/kg
Number of subjects: 0
Study 29488121 — intervention group
Group type: EXPERIMENTAL
Intervention: PACX (paclitaxel/capecitabine)
Number of subjects: 320
Study 29488121 — intervention group
Group type: COMPARATOR
Intervention: XP (cisplatin/capecitabine)
Number of subjects: 320
Study 26856191 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS) inhalation
Number of subjects: 21
Study 26856191 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (IS) inhalation
Number of subjects: 21
Study 24145220 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 51
Study 24145220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 22530354 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg/week) + Teriparatide (20 mg)
Number of subjects: 20
Study 22530354 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (50 mg/week)
Number of subjects: 20
Study 21092228 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy diet + exercise
Number of subjects: 141
Study 21092228 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate, high protein diet + exercise
Number of subjects: 141
Study 21092228 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate, moderate protein diet + exercise
Number of subjects: 141
Study 21092228 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate, low protein diet + exercise
Number of subjects: 141
Study 21092228 — intervention group
Group type: EXPERIMENTAL
Intervention: No diet + exercise
Number of subjects: 141
Study 21092228 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction + exercise (all groups)
Number of subjects: 141
Study 21092228 — intervention group
Group type: COMPARATOR
Intervention: No diet + no exercise control group (CON)
Number of subjects: 141
Study 21092228 — intervention group
Group type: COMPARATOR
Intervention: No diet + exercise control (ND)
Number of subjects: 141
Study 18502991 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol-dorzolamide fixed combination (TDFC)
Number of subjects: 27
Study 18502991 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 27
Study 18502991 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol-dorzolamide fixed combination (TDFC) and Latanoprost 0.005%
Number of subjects: 27
Study 15933983 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable valvulotome
Number of subjects: 30
Study 15933983 — intervention group
Group type: COMPARATOR
Intervention: Fixed valvulotome
Number of subjects: 30
Study 12913687 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming of the abdomen and lower back region (42C)
Number of subjects: 100
Study 12913687 — intervention group
Group type: COMPARATOR
Intervention: No warming
Number of subjects: 100
Study 10215732 — intervention group
Group type: COMPARATOR
Intervention: LAC (lansoprazole 30 mg b.d., amoxycillin 500 mg b.d., clarithromycin 400 mg b.d. for 7 days)
Number of subjects: 66
Study 10215732 — intervention group
Group type: EXPERIMENTAL
Intervention: LACP (LAC regimen plus polaprezinc 150 mg b.d. for 7 days)
Number of subjects: 66
Study 10215732 — intervention group
Group type: COMPARATOR
Intervention: LAC (lansoprazole, amoxycillin, clarithromycin)
Number of subjects: 66
Study 10215732 — intervention group
Group type: EXPERIMENTAL
Intervention: LACP (LAC plus polaprezinc)
Number of subjects: 66
Study 7869193 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LH‐RH) stimulation tests in children with NF‐1 and OPTs
Number of subjects: 219
Study 7869193 — intervention group
Group type: COMPARATOR
Intervention: Luteinizing hormone-releasing hormone (LH‐RH) stimulation tests in children without OPTs (control group)
Number of subjects: 219
Study 1694235 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy regimens (MOPP/ABVD; CAD plus MOPP plus ABV) combined with intermediate-dose radiation therapy (RT)
Number of subjects: 185
Study 1694235 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with two or more unfavorable characteristics
Number of subjects: 185
Study 1694235 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with none or only one unfavorable factor
Number of subjects: 185
Study 621612 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil stable dose (0.2 mg/kg/day) for 56 to 60 days
Number of subjects: 21
Study 621612 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil increasing doses (0.2 to 0.63 mg/kg/day) for 42 to 77 days
Number of subjects: 21
Study 621612 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg/m2 on alternate days)
Number of subjects: 21
Study 29927884 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraceptives (HC)
Number of subjects: 18
Study 29927884 — intervention group
Group type: COMPARATOR
Intervention: Never used hormonal contraceptives (NHC)
Number of subjects: 18
Study 30422390 — intervention group
Group type: EXPERIMENTAL
Intervention: Praliciguat (15/30 mg, 20/40 mg, 30/40 mg, and weight-based)
Number of subjects: 44
Study 30422390 — intervention group
Group type: EXPERIMENTAL
Intervention: Praliciguat
Number of subjects: 44
Study 30422390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 28695804 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular Tai Chi exercise (group B)
Number of subjects: 614
Study 28695804 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 600 mg/d + VitD3 800 U/d (group C)
Number of subjects: 614
Study 28695804 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 600 mg/d + 25 hydroxyl vitamin D (25OHD) 0.25 μg/d (group D)
Number of subjects: 614
Study 28695804 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 614
Study 26679652 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 g sucrose gel
Number of subjects: 533
Study 26679652 — intervention group
Group type: COMPARATOR
Intervention: 5.0 g metronidazole gel
Number of subjects: 533
Study 23389750 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 22
Study 23389750 — intervention group
Group type: COMPARATOR
Intervention: Control ITP patients
Number of subjects: 22
Study 21695906 — intervention group
Group type: EXPERIMENTAL
Intervention: sports intervention
Number of subjects: 232
Study 21695906 — intervention group
Group type: EXPERIMENTAL
Intervention: diet intervention
Number of subjects: 232
Study 21695906 — intervention group
Group type: EXPERIMENTAL
Intervention: sports and diet intervention
Number of subjects: 232
Study 21695906 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 232
Study 19091346 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg finasteride daily for at least 30 days before surgery
Number of subjects: 42
Study 19091346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17407636 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily (BID)
Number of subjects: 377
Study 17407636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study 17407636 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg BID
Number of subjects: 377
Study 15379878 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light irradiation
Number of subjects: 31
Study 15379878 — intervention group
Group type: COMPARATOR
Intervention: Control (non-irradiation side)
Number of subjects: 31
Study 11172832 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times daily for 7 weeks)
Number of subjects: 27
Study 11172832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9645591 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose inhaled fluticasone propionate (250 microg b.d.)
Number of subjects: 23
Study 9645591 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 23
Study 8942333 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1 during desflurane anaesthesia
Number of subjects: 0
Study 8942333 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1 during isoflurane anaesthesia
Number of subjects: 0
Study 8942333 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium during desflurane anaesthesia
Number of subjects: 0
Study 8942333 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium during isoflurane anaesthesia
Number of subjects: 0
Study 2332814 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 49
Study 2332814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 518290 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend workshops on sex education
Number of subjects: 0
Study 518290 — intervention group
Group type: COMPARATOR
Intervention: No-program control group
Number of subjects: 0
Study 30243853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU twice daily)
Number of subjects: 68
Study 30243853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 28107408 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation with 8 cmH2O PEEP (PEEP group)
Number of subjects: 38
Study 28107408 — intervention group
Group type: COMPARATOR
Intervention: Low tidal volume ventilation without PEEP (ZEEP group)
Number of subjects: 38
Study 24725075 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS intervention with 10 consecutive sessions, allowing for 2 nonconsecutive missed visits
Number of subjects: 120
Study 24725075 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS intervention with 10 consecutive sessions
Number of subjects: 120
Study 24725075 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS intervention
Number of subjects: 120
Study 22701297 — intervention group
Group type: EXPERIMENTAL
Intervention: LCR35 at least 108 CFU/day (group 1)
Number of subjects: 20
Study 22701297 — intervention group
Group type: EXPERIMENTAL
Intervention: LCR35 at 2 × 108 CFU/day (group 2)
Number of subjects: 20
Study 20844187 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling provided for mothers during 10 home visits in the first year of life
Number of subjects: 500
Study 18378374 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic medication (on)
Number of subjects: 12
Study 18378374 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic medication (off)
Number of subjects: 12
Study 18378374 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study 18378374 — intervention group
Group type: EXPERIMENTAL
Intervention: Time reproduction task
Number of subjects: 12
Study 18378374 — intervention group
Group type: EXPERIMENTAL
Intervention: Warned reaction time task
Number of subjects: 12
Study 16706961 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (target INR 1.5-2.0)
Number of subjects: 508
Study 16706961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508
Study 16706961 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated D-dimer
Number of subjects: 508
Study 16706961 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated FVIIIc
Number of subjects: 508
Study 16706961 — intervention group
Group type: COMPARATOR
Intervention: One prior VTE on placebo
Number of subjects: 508
Study 16706961 — intervention group
Group type: EXPERIMENTAL
Intervention: More than one prior VTE
Number of subjects: 508
Study 16706961 — intervention group
Group type: EXPERIMENTAL
Intervention: One prior VTE
Number of subjects: 508
Study 12905053 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg Solu‐Medrol intravenously and 160 mg Depo‐Medrol intramuscularly, plus 80 mg Depo‐Medrol on the dural sac
Number of subjects: 80
Study 12905053 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride instead of Depo‐Medrol
Number of subjects: 80
Study 10977010 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 21
Study 10977010 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium supplementation after 3 months of metformin therapy
Number of subjects: 21
Study 10977010 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study 7488478 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration with ketorolac 30 mg in saline
Number of subjects: 32
Study 7488478 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration with ketorolac 30 mg with 0.25% bupivacaine
Number of subjects: 32
Study 7488478 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration with 0.25% bupivacaine
Number of subjects: 32
Study 7488478 — intervention group
Group type: COMPARATOR
Intervention: Control group (ketorolac 60 mg i.m.)
Number of subjects: 32
Study 2285455 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational session consisting of a 40-minute session with a 10-minute video presentation and discussion by the teacher on BP.
Number of subjects: 0
Study 2285455 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute videotape and complementary print program guide.
Number of subjects: 0
Study 6118830 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg bromazepam
Number of subjects: 55
Study 6118830 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg bromazepam
Number of subjects: 55
Study 6118830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31154292 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious sedation
Number of subjects: 350
Study 31154292 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 350
Study 28403335 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle (G3)
Number of subjects: 180
Study 28403335 — intervention group
Group type: EXPERIMENTAL
Intervention: Seed (G2)
Number of subjects: 180
Study 28403335 — intervention group
Group type: COMPARATOR
Intervention: Control (G1)
Number of subjects: 180
Study 28403335 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape (G4)
Number of subjects: 180
Study 26459358 — intervention group
Group type: EXPERIMENTAL
Intervention: FES treatment group (n = 16)
Number of subjects: 32
Study 26459358 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 32
Study 24261693 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt abdominal entry
Number of subjects: 0
Study 24261693 — intervention group
Group type: EXPERIMENTAL
Intervention: Exteriorisation of the uterus for repair
Number of subjects: 0
Study 24261693 — intervention group
Group type: EXPERIMENTAL
Intervention: Single layer closure of the uterus
Number of subjects: 0
Study 24261693 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of the peritoneum
Number of subjects: 0
Study 24261693 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromic catgut for uterine repair
Number of subjects: 0
Study 24261693 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's health outcomes
Number of subjects: 0
Study 24261693 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent pregnancy outcomes
Number of subjects: 0
Study 21496936 — intervention group
Group type: EXPERIMENTAL
Intervention: Group MVB: zinc (20 mg), magnesium (250 mg), vitamin C (200 mg), vitamin E (100 mg), vitamin B1 (10 mg), B2 (10 mg), B6 (10 mg), biotin (200 μg), B12 (10 μg), folic acid (1 mg)
Number of subjects: 75
Study 21496936 — intervention group
Group type: EXPERIMENTAL
Intervention: Group MV: zinc (20 mg), magnesium (250 mg), vitamin C (200 mg), vitamin E (100 mg)
Number of subjects: 75
Study 21496936 — intervention group
Group type: COMPARATOR
Intervention: Group P: placebo
Number of subjects: 75
Study 19969161 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Coping Planning (ACP)
Number of subjects: 44
Study 19969161 — intervention group
Group type: COMPARATOR
Intervention: Action Planning Only (APO)
Number of subjects: 44
Study 17718106 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton CR, 1,200 mg twice daily
Number of subjects: 613
Study 17718106 — intervention group
Group type: COMPARATOR
Intervention: Placebo CR, twice daily
Number of subjects: 613
Study 15028073 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF group
Number of subjects: 9
Study 15028073 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9
Study 15028073 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (300 mg/day)
Number of subjects: 9
Study 11440290 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.5% fluorouracil once daily for up to 28 days
Number of subjects: 21
Study 11440290 — intervention group
Group type: COMPARATOR
Intervention: Topical 5% fluorouracil twice daily for up to 28 days
Number of subjects: 21
Study 9505769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus of 5 ml of 0.375% bupivacaine hourly
Number of subjects: 48
Study 9505769 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of 5 ml of 0.375% bupivacaine hourly
Number of subjects: 48
Study 7829766 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (20 mg, orally, twice daily)
Number of subjects: 0
Study 7829766 — intervention group
Group type: COMPARATOR
Intervention: Buspirone challenge paradigm
Number of subjects: 0
Study 2894164 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine 1 mg/day
Number of subjects: 126
Study 2894164 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine 1 mg twice a day
Number of subjects: 126
Study 2894164 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 126
Study 29883974 — intervention group
Group type: EXPERIMENTAL
Intervention: intralipid/heparin infusion
Number of subjects: 20
Study 29883974 — intervention group
Group type: COMPARATOR
Intervention: saline infusion (placebo)
Number of subjects: 20
Study 27172830 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine (<8 mg/24 h)
Number of subjects: 247
Study 27172830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247